Orca-T Leads to Retrospective OS Improvement in High-Risk Hematologic Malignancies After Allo-HCT
Orca-T was retrospectively associated with improved OS in patients with high-risk hematologic malignancies undergoing allogeneic stem cell transplant.
Related Articles
ctDNA, Neoadjuvant Immunotherapy Combos Could Help Reshape Management of CRC
Stacey A. Cohen, MD, provides an overview on the current landscape of immunotherapies and prognostic tools in the treatment of colorectal cancer.
Sharing AI insights without sharing patient data
The new Cancer AI Alliance includes Fred Hutch, Dana-Farber, Memorial Sloan Kettering, The Sidney Kimmel Comprehensive Cancer Center and the Whiting School of Engineering at…
Surgeon General Aims to Reduce Alcohol-Related Cancers in the US
“Alcohol is a well-established, preventable cause of cancer responsible for about 100,000 cases of cancer and 20,000 cancer deaths annually in the United States,” said…
2/21/2025 – 2025 Gastrointestinal Oncology Symposium
Medical information is constantly being updated and new clinical trials reported. Treatment algorithms and clinical guidelines are modified year-round at specialty conferences and by national…
Prevalence of Psychiatric Disorders High in Patients With Breast Cancer – Oncology Nurse Advisor
Researchers investigated the prevalence of psychiatric disorders and need for psycho-oncology support among patients with breast cancer.
2024 Most Read Articles | Blood Advances | American Society of Hematology
2024 Most Read Articles | Blood Advances | American Society of Hematology Top Ten Most Read Articles in 2024 Blood Advances is pleased to announce…
How I treat ETP-ALL in children
Edited by Associate Editor Hervé Dombret, this How I Treat series highlights the clinical approach to high-risk subgroups of acute lymphoblastic leukemia (
Osimertinib Vs Amivantamab Combos in EGFR/TP53-Mutated NSCLC
A panel of experts met to discuss the best treatment options for patients with EGFR or TP53-mutated non–small cell lung cancer.
